In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.
ASCO 2025 Highlights Guests: Charu Aggarwal, MD, MPH Leslye M. Heisler Professor of Medicine Section Chief, Thoracic and Head & Neck Cancer Associate Director, Penn Center for Cancer Care Innovation (PC3I) University of Pennsylvania Patrick Forde, MBBCh Associate Professor Johns Hopkins University
In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.
LCC in Korean: Lung Cancer Updates & Future Directions by IASLC
Global Advances and Persistent Disparities in Lung Cancer Treatment by IASLC
Dr. Bryant Lin Teaching My Cancer by IASLC
AACR 2025 Highlights by IASLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Mihaela Aldea about the key information about RET-positive NSCLC, from diagnostic challenges to treatment selection. Join us in this lively discussion.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Eric Singhi and Dr. Misty Shields about patient education and communication. Tune in to hear the top things to discuss during your first oncology visit, including conflict and miscommunication resolution.
Guest: Dr. Corey Langer is the Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania
LCC in Korean: 2024 Lung Cancer Updates by IASLC
LCC in Mandarin: Virtual Tumor Board - EGFR NSCLC by IASLC
LCC in Italian: Virtual Tumor Board - Resectable NSCLC by IASLC
Virtual Tumor Board: Targeting Residual Disease by IASLC
The Microbiome and Immunotherapy for Lung Cancer by IASLC
This episode of Lung Cancer Considered takes an in-depth look at thymoma and thymic carcinomas, both challenging diseases to treat with evolving new therapeutics. Join host Dr. Narjust Florez and guests, Dr. Claudia Proto and Dr. Kim Chul, for a discussion of these understudied and potentially poorly understood diseases.
Live from TTLC25: Lung Cancer and Brain Metastasis by IASLC
Host: Ece Cali Daylan, Assistant Professor of Medicine, Division of Oncology at Washington University School of Medicine Guest: Saadettin Kilickap Guest: Ozden Altundag
As part of IASLC's ongoing series of podcasts in world languages, Dr. Balazs Halmos moderates a discussion in Hungarian with Dr. Krisztina Bogos, Dr. Ferenc Rényi-Vámos and Dr. Zsolt Megyesfalvi. The podcast reviews recent advances in lung cancer screening, diagnosis and management with a particular focus on implementation in Hungary. Highlights of the discussion include novel staging and diagnostic tools, state-of-the-art biomarker testing, perioperative therapy and clinical trials access. Host...
The 2024 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Sally Lau moderates a discussion in Cantonese Chinese about highlights from the conference with Dr. David Lee and Dr. Molly Li.
Virtual Tumor Board: Stage III ALK+ NSCLC by IASLC
Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate by IASLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez engages in a discussion with patient advocate Summer Farmen. Listen to the episode to learn about Summer’s journey through diagnosis and treatment, and the importance of patient advocate groups. • Summer Farmen ALKtALK Program Coordinator Board Member, ALK Positive, Inc.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on how small cell lung cancer continues to evolve with new treatment options and recent FDA approval. Listen to the episode to learn about the current standard of care and future therapies with a brief discussion about small cell transformation. Guest: Triparna Sen, MD Associate Professor Director, Lung Cancer PDX Program, Icahn School of Medicine at Mount Sinai Guest: Jacob Sands, MD Assistant Professor of Med...
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to learn about the role of next-generation sequencing in diagnosis and treatment selection, as well as current and future targeted therapy in the management of both. Guests Melina Marmarelis, MD MSCE Assistant Professor Medical Director, UPenn Mesothelioma University of Pennsylvania Jia Luo, MD Medical O...
Descriptions: As part of the IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Bashir Abu Aqeel and Dr. Fawzi Abu Rous. The group discusses chemoimmunotherapy in metastatic non-small cell lung cancer.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC. This discussion takes the listener through the treatment of EGFR mutant NSCLC after acquired resistance to osimertinib. Guest: Dr. Yasushi Goto from National Cancer Center, Japan in Tokyo Guest: Dr. Rachel Sanborn, the Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon
This episode of Lung Cancer Considered covers the recent FDA approval of Osimertinib after chemo-radiation in EGFR positive NSCLC based on the LAURA trial which was presented at the 2024 ASCO Annual Meeting. Host Dr. Narjust Florez goes in depth with podcast guest Dr. Pamela Samson about the LAURA Trial and its implications for patients and clinicians. Guest: Dr. Pamela Samson is an assistant professor in the Department of Radiation Oncology at Washington University in St. Louis. Dr. Samson spec...
En este episodio de Lung Cancer Considered, vamos a hablar sobre el cancer de pulmón en México. Tengo el placer de tener en este episodio dos doctores con mucha experiencia tratando y entendiendo las necesidades de los pacientes con cancer de pulmón en México. Este episodio es una introducción y esperamos tener conversaciones as profundas en el futuro. Bio: Tenemos al Dr. Jorge Alatorre, Oncology clínico con Alta especialidad en Tumores del Tórax (Cáncer de pulmón y Mesotelioma). Y es jefe del S...
Description: As part of IASLC’s commitment to communicating in all world languages, this episode of Lung Cancer Considered is recorded in German and is part of our Virtual Tumor Board series. Host Professor Alessandra Curioni-Fontecedro moderates a discussion with two colleagues, who will discuss the dynamic topic of managing resectable stage III NSCLC. Host: Prof Alessandra Curioni-Fontecedro, MD, Head of Oncology, Cantonal Hospital Fribourg, Chair of Medical Oncology, University of Fribourg Gu...
